


GSK Q2 2017 results



Sales across all 3 businesses



New product sales

£1.7bn

+62% AER, +47% CER

Group operating margin

28.5%

Total EPS

-3.7p

+29% CER

Adjusted EPS

27.2p

-2% CER

Free cash flow
H1 2017

£0.4bn

Dividend

19p



See [press release](http://www.gsk.com) on www.gsk.com for details on Q2 2017
Please read the cautionary statement regarding **forward-looking statements**

The *Ellipta*[®] inhaler